{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:20:24Z","timestamp":1760149224136,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Economy and Competitiveness","award":["JE21\/00027"],"award-info":[{"award-number":["JE21\/00027"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>The screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and AEs for LTBI patients at two departments in Vall d\u2019Hebron University Hospital in Barcelona, Spain. A retrospective study was conducted on all persons treated for LTBI between January 2018 and December 2020. Variables collected included demographics, the reason for LTBI screening and treatment initiation, AEs related to treatment, and treatment outcome. Out of 261 persons who initiated LTBI treatment, 145 (55.6%) were men, with a median age of 42.1 years. The indications for LTBI screening were household contact of a TB case in 96 (36.8%) persons, immunosuppressive treatment in 84 (32.2%), and recently arrived migrants from a country with high TB incidence in 81 (31.0%). Sixty-three (24.1%) persons presented at least one AE during treatment, and seven (2.7%) required definitive discontinuation of treatment. In the multivariate analysis, AE development was more frequent in those who started LTBI treatment due to immunosuppression. Overall, 226 (86.6%) completed treatment successfully. We concluded that LTBI screening and treatment groups had different risks for adverse events and treatment outcomes. Persons receiving immunosuppressive treatment were at higher risk of developing AEs, and recently arrived immigrants from countries with a high incidence of TB had greater LTFU. A person-centered adherence and AE management plan is recommended.<\/jats:p>","DOI":"10.3390\/tropicalmed8070373","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T21:21:46Z","timestamp":1689801706000},"page":"373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain"],"prefix":"10.3390","volume":"8","author":[{"given":"Juan David","family":"Puyana Ortiz","sequence":"first","affiliation":[{"name":"International Health and Cooperation UAB, 08193 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9393-1220","authenticated-orcid":false,"given":"Andrea Carolina Garc\u00e9s","family":"Garc\u00e9s Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Morales Meseguer University Hospital, 30008 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9223-7790","authenticated-orcid":false,"given":"Mar\u00eda Luisa","family":"Aznar","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Grupo de Estudio de Micobacterias (GEIM), Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC), 28003 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-8337","authenticated-orcid":false,"given":"Juan","family":"Espinosa Pereiro","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Grupo de Estudio de Micobacterias (GEIM), Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC), 28003 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez-Montalv\u00e1","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Grupo de Estudio de Micobacterias (GEIM), Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC), 28003 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-8447","authenticated-orcid":false,"given":"Joan","family":"Mart\u00ednez-Campreci\u00f3s","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-3597","authenticated-orcid":false,"given":"Nuria","family":"Saborit","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Rodrigo-Pend\u00e1s","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Epidemiology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Garc\u00eda Salgado","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Broto","family":"Broto Cortes","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria Serre","family":"Delcor","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Oliveira","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-8288","authenticated-orcid":false,"given":"Bego\u00f1a Trevi\u00f1o","family":"Trevi\u00f1o Maruri","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Pou","family":"Ciruelo","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-1829","authenticated-orcid":false,"given":"Pau","family":"Bosch-Nicolau","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Torrecilla-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Epidemiology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-4321","authenticated-orcid":false,"given":"Ricardo","family":"Zules-O\u00f1a","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Epidemiology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-298X","authenticated-orcid":false,"given":"Mar\u00eda Teresa T\u00f3rtola","family":"T\u00f3rtola Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Microbiology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Molina","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d\u2019Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022). Global Tuberculosis Report 2022, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Houben, R.M.G.J., and Dodd, P.J. (2016). The Global Burden of Latent Tuberculosis Infection: A Re-Estimation Using Mathematical Modelling. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002152"},{"key":"ref_3","unstructured":"World Health Organization (2018). Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management, World Health Organization."},{"key":"ref_4","unstructured":"WHO (2020). WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention\u2014Tuberculosis Preventive Treatment, World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_6","unstructured":"Organizaci\u00f3n Mundial de la Salud (2014). Directrices Sobre la Atenci\u00f3n de la Infecci\u00f3n Tuberculosa Latente, Organizaci\u00f3n Mundial de la Salud."},{"key":"ref_7","first-page":"e201808057","article-title":"Cumplimiento Del Tratamiento de La Infecci\u00f3n Tuberculosa Latente En Una Cohorte de Contactos de Enfermos de Tuberculosis","volume":"92","author":"Godoy","year":"2018","journal-title":"Rev. Espa\u00f1ola De Salud P\u00fablica"},{"key":"ref_8","first-page":"53","article-title":"Infecci\u00f3n latente por Mycobacterium tuberculosis y adherencia al tratamiento en una cohorte de pacientes pretrasplante renal","volume":"6","year":"2017","journal-title":"Rev. Mex. Traspl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S1473-3099(21)00052-9","article-title":"Initiation and Completion of Treatment for Latent Tuberculosis Infection in Migrants Globally: A Systematic Review and Meta-Analysis","volume":"21","author":"Rustage","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","article-title":"A Prospective Clinical Study of Isoniazid-Rifampicin-Pyrazinamide-Induced Liver Injury in an Area Endemic for Hepatitis B","volume":"12","author":"Hwang","year":"1997","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_11","unstructured":"(2023, January 07). Quimioterapia de la Tuberculosis, la Enfermedad Causada Por el Complejo de Mycobacterium Avium, y la Lepra | Goodman & Gilman: Las Bases Farmacol\u00f3gicas de la Terap\u00e9utica, 12e | AccessMedicina | McGraw Hill Medical. Available online: https:\/\/accessmedicina.mhmedical.com\/content.aspx?bookid=1882&sectionid=138617348."},{"key":"ref_12","unstructured":"(2023, January 07). Rifamycins (Rifampin, Rifabutin, Rifapentine)\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/rifamycins-rifampin-rifabutin-rifapentine?search=rifampicina&source=search_result&selectedTitle=2~148&usage_type=default&display_rank=1."},{"key":"ref_13","unstructured":"(2023, January 07). Isoniazid: An Overview\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/isoniazid-an-overview?search=isoniazida&source=search_result&selectedTitle=2~148&usage_type=default&display_rank=1."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eimc.2017.10.006","article-title":"Tuberculosis e inmigraci\u00f3n","volume":"36","author":"Salvador","year":"2018","journal-title":"Enfermedades Infecc. Microbiol. Cl\u00ednica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1183\/09031936.00216814","article-title":"Monitoring Toxicity in Individuals Receiving Treatment for Latent Tuberculosis Infection: A Systematic Review versus Expert Opinion","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_16","unstructured":"Inicio (2023, January 08). Vall d\u2019Hebron Barcelona Hospital Campus. Available online: https:\/\/www.vallhebron.com\/es\/inicio."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-Associated Hepatitis. Report of an Outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of Latent Tuberculosis Infection: An Updated Network Meta-Analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eimc.2017.11.014","article-title":"Diagnosis and Therapeutic Approach of Latent Tuberculosis Infection","volume":"36","author":"Latorre","year":"2018","journal-title":"Enfermedades Infecc. Microbiol. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of Tuberculosis Reactivation during Interleukin-17 Inhibitor Therapy for Psoriasis: A Systematic Review","volume":"34","author":"Fowler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e022445","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and Prevention for Latent Tuberculosis in Immunosuppressed Patients at Risk for Tuberculosis: A Systematic Review of Clinical Practice Guidelines","volume":"8","author":"Hasan","year":"2018","journal-title":"BMJ Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000001224","article-title":"Prevention and Management of Tuberculosis in Transplant Recipients: From Guidelines to Clinical Practice","volume":"100","author":"Santin","year":"2016","journal-title":"Transplantation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e3442","DOI":"10.1590\/1518-8345.3839.3442","article-title":"Prevalencia de tuberculosis latente y factores asociados en pacientes con enfermedad renal cr\u00f3nica en hemodi\u00e1lisis","volume":"29","author":"Ferreira","year":"2021","journal-title":"Rev. Latino-Am. Enfermagem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.ackd.2018.09.004","article-title":"Mycobacterial Infections in Patients with Chronic Kidney Disease and Kidney Transplantation","volume":"26","author":"Brust","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1532-5415.2002.50308.x","article-title":"Tuberculosis in Older People: A Retrospective and Comparative Study from Hong Kong","volume":"50","author":"Leung","year":"2002","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk Factors for Side-Effects of Isoniazid, Rifampin and Pyrazinamide in Patients Hospitalized for Pulmonary Tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1503\/cmaj.091824","article-title":"Adverse Events Associated with Treatment of Latent Tuberculosis in the General Population","volume":"183","author":"Smith","year":"2011","journal-title":"CMAJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, Clinical Features, and Outcomes from a Prospective Study of Drug-Induced Liver Injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_30","first-page":"144","article-title":"Incidence and Risk Factors of Major Toxicity Associated to First-Line Antituberculosis Drugs for Latent and Active Tuberculosis during a Period of 10 Years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev. Port. Pneumol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1513\/AnnalsATS.201908-623OC","article-title":"Tuberculosis among Newly Arrived Immigrants and Refugees in the United States","volume":"17","author":"Liu","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4067\/S0717-73482020000300215","article-title":"Experiencia Piloto Con Esquema Rifapentina-Isoniazida Semanal Por 3 Meses Para Tratamiento de La Infecci\u00f3n Tuberculosa Latente En El Programa Nacional de Tuberculosis de Chile","volume":"36","author":"Herrera","year":"2020","journal-title":"Rev. Chil. Enfermedades Respir."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10461-010-9871-0","article-title":"Reluctance to Do Blood Testing Limits HIV Diagnosis and Appropriate Health Care of Sub-Saharan African Migrants Living in Spain","volume":"16","author":"Navaza","year":"2012","journal-title":"AIDS Behav."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1708-8305.2009.00312.x","article-title":"Dead Blood under My Skin","volume":"16","author":"Scarcella","year":"2009","journal-title":"J. Travel Med."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/7\/373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:15:02Z","timestamp":1760127302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/7\/373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["tropicalmed8070373"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed8070373","relation":{},"ISSN":["2414-6366"],"issn-type":[{"type":"electronic","value":"2414-6366"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}